LONDON – Mereo Biopharma Ltd. has raised $119 million in a series A round after agreeing to acquire three clinical-stage programs from Novartis AG. Read More
Following Biogen Inc.'s lackluster report last week, Gilead Sciences Inc. is getting the second quarter biotechnology earnings season back on track, reporting its financial results after the markets closed on Tuesday. Read More
Ariad Pharmaceuticals Inc. agreed to pay mid-single-digit royalties on futures sales of Iclusig (ponatinib) to PDL Biopharma Inc. in exchange for up to $200 million in financing intended to accelerate testing of brigatinib, an anaplastic lymphoma kinase (ALK) inhibitor it is developing to treat non-small-cell lung cancer (NSCLC), and to continue its ongoing initiatives supporting both drugs. Read More
HONG KONG – The CFDA is getting closer to completing a new revision of the country's Pharmaceutical Administration Law. After drastically increasing the registration fees for pharmaceuticals this year, the CFDA is now soliciting opinions on a draft guideline for the registration inspection of imported pharmaceutical products. Read More
TAIPEI, Taiwan – China's fast-growing health care sector presents excellent opportunities for industry collaboration for overseas companies. And Taiwan, with its existing cultural, language and business ties with China, is particularly well placed to take advantage of those conditions. Read More
The World Health Organization (WHO) and other international organizations are calling on vaccine makers to increase production of meningitis C vaccines by 5 million doses before the 2016 meningitis season starts in January. Read More
Dermira Inc., of Menlo Park, Calif., filed with the SEC to raise up to $97.8 million in a public offering, though the number of shares and share price have not yet been disclosed. Read More
The Medicines Co., of Parsippany, N.J., reported worldwide net revenue of $90.5 million for the second quarter, a significant drop from the $183.8 million reported for the same period in 2014, which the company attributed to purchasers continuing to hold out for generic versions of anticoagulant Angiomax (bivalirudin). Read More
Bellerophon Therapeutics Inc., of Hampton, N.J., expanded its license agreement with Dublin-based Mallinckrodt plc division Ino Therapeutics LLC, allowing Bellerophon to develop Inopulse, a drug-device combination system designed to reduce pulmonary hypertension (PH), for the treatment of three additional cardiopulmonary diseases, including chronic thromboembolic PH, PH associated with sarcoidosis and PH associated with pulmonary edema from high altitude sickness. Read More
Kalobios Pharmaceuticals Inc., of South San Francisco, said the FDA cleared the investigational new drug application for its anti-granulocyte macrophage colony-stimulating factor, or GM-CSF, monoclonal antibody, KB003, enabling the company to initiate its open-label phase I study to evaluate safety, pharmacokinetics and clinical activity in previously treated patients with chronic myelomonocytic leukemia. Read More
